1. Home
  2. AIRS vs KZIA Comparison

AIRS vs KZIA Comparison

Compare AIRS & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AirSculpt Technologies Inc.

AIRS

AirSculpt Technologies Inc.

HOLD

Current Price

$1.42

Market Cap

182.4M

Sector

Health Care

ML Signal

HOLD

Logo Kazia Therapeutics Limited

KZIA

Kazia Therapeutics Limited

HOLD

Current Price

$7.39

Market Cap

186.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AIRS
KZIA
Founded
2012
1994
Country
United States
Australia
Employees
N/A
N/A
Industry
Medical/Nursing Services
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
182.4M
186.7M
IPO Year
2021
2002

Fundamental Metrics

Financial Performance
Metric
AIRS
KZIA
Price
$1.42
$7.39
Analyst Decision
Hold
Strong Buy
Analyst Count
3
6
Target Price
$4.50
★ $28.33
AVG Volume (30 Days)
★ 838.4K
261.5K
Earning Date
11-06-2026
11-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $151,818,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$2.65
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$1.41
$4.86
52 Week High
$12.00
$17.40

Technical Indicators

Market Signals
Indicator
AIRS
KZIA
Relative Strength Index (RSI) 26.01 28.65
Support Level N/A $6.82
Resistance Level $2.03 $8.18
Average True Range (ATR) 0.13 0.63
MACD 0.00 -0.13
Stochastic Oscillator 5.43 20.05

Price Performance

Historical Comparison
AIRS
KZIA

About AIRS AirSculpt Technologies Inc.

AirSculpt Technologies Inc is a next-generation body contouring treatment designed to optimize both comfort and precision, available exclusively at AirSculpt offices. The minimally invasive procedure removes fat and tightens skin while sculpting targeted areas of the body, allowing for quick healing with minimal bruising, tighter skin, and precise results. Its proprietary and patented AirSculpt method is minimally invasive because it requires no needle, no scalpel, no stitches, and no general anesthesia. It offers fat removal procedures across treatment areas and fat transfer procedures that use the patient's own fat cells to enhance the breasts, buttocks, hips or other areas and do not require silicone or foreign materials to be implanted. Its segment is direct medical procedure services.

About KZIA Kazia Therapeutics Limited

Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.

Share on Social Networks: